Landes Bioscience has announced the start of a new peer-reviewed journal, Biopharmaceuticals, with its first issue to be published in early 2011. Biopharmaceuticals will be the first peer-reviewed periodical solely concerned with biopharmaceuticals, the most complex of all commercial products. Individual online subscriptions will be free during the first year.
Biopharmaceuticals are pharmaceuticals manufactured by or using living organisms. Biopharmaceuticals are rapidly increasing in number and importance, with over 600 currently marketed in the U.S. and European markets alone, a large number in development, and their number and percentage steadily increasing relative to small-molecule drugs. The discovery, development, manufacture and marketing of biopharmaceuticals require an integrated understanding of their scientific, technological and commercial/societal aspects. Only those most knowledgeable concerning the diverse aspects of these products will be successful. The situation is getting even more complex as large numbers of biosimilars and biogenerics enter markets worldwide.
Mr. Ronald A. Rader, editor-in-chief, notes, "Biopharmaceuticals is designed to serve the information needs of those involved with biopharmaceutical research, development, regulation, technology transfer and marketing. Articles will go beyond reporting laboratory findings and include discussions of the relevance of new scientific findings, technologies, regulations, patents, products and marketing trends. This includes reviews, reports, commentaries and case studies in diverse areas, including the nature and characterization of biopharmaceuticals, agent discovery and design, issues in product development, financing, clinical testing, regulatory approvals, patents and licensing, manufacturing, technology and market assessments and projections, scientific controversies and politics."
Articles are now being accepted for review and publication. There are no page or other publication charges during the first year. Volunteers are also needed to serve on the Editorial Board and host topical sections. For further information, contact:
Ronald A. Rader
Editor-in-Chief, Biopharmaceuticals
Landes Bioscience
Phone: 301-424-0255
E-mail: rader@landesbioscience.com
Journal website: www.landesbioscience.com/journals/biopharma/
Source: Landes Bioscience
When sports chiropractors first appeared at the Olympic Games in the 1980s, it was alongside individual athletes who had experienced the benefits of chiropractic care in their training and recovery processes at home. Fast forward to Paris 2024, where chiropractic care was available in the polyclinic for all athletes, and the attitude has now evolved to recognize that “every athlete deserves access to sports chiropractic."
It is estimated that 61% of patients with CTS avoid taking surgical options due to postoperative complications and costly surgical procedures. Chiropractic care offers a comprehensive and effective treatment for carpal tunnel syndrome, addressing the condition from multiple angles. Recent studies also have unveiled a game-changing adjunct to chiropractic treatments for CTS: nerve flossing.
Some doctors thrive in a personality-based clinic and have a loyal following no matter what services or equipment they offer, but for most chiropractic offices who are trying to grow and expand, new equipment purchases help us stay relevant and continue to service our client base in the best, most up-to-date manner possible. So, regarding equipment purchasing: should you lease, get a bank loan, or pay cash?
